Latest Breaking News On - Sylvain durrleman - Page 1 : comparemela.com

Moleac s NeuroAiD™II Improves Post-Concussion Symptoms,

Moleac s NeuroAiD™II Improves Post-Concussion Symptoms,
globenewswire.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from globenewswire.com Daily Mail and Mail on Sunday newspapers.

David picardValery feiginSylvain durrlemanName of press contactHead of medical affairs at moleacWorld congressProfessor valery feiginRivermead post concussion symptoms questionnaireBrain injuryHospital anxietyDepression scaleMedical affairsPress contact

Moleac s NeuroAiD™II Improves Post-Concussion Symptoms, Quality of Life, and Mood after a Mild Traumatic Brain Injury

With its targeted multimodal approach, NeuroAiD™II offers a broad range of therapeutic benefits to TBI patients.NeuroAiD™II was well-tolerated by TBI patients with a favourable safety profile. SINGAPORE, Dec. 04, 2023 (GLOBE NEWSWIRE) Moleac announced promising results from the SAMURAI double-blind study in patients with mild traumatic brain injury (mTBI) receiving a 6-month course of NeuroAiD™II. In the study, the NeuroAiD™II group showed significant improvement in their post-concussion symp

David picardValery feiginSylvain durrlemanName of press contactHead of medical affairs at moleacWorld congressProfessor valery feiginRivermead post concussion symptoms questionnaireBrain injuryHospital anxietyDepression scaleMedical affairsPress contactMild traumatic brain injuryAvourable safety profileTherapeutic benefits

Moleac Pte Ltd: Moleac s NeuroAiDII Improves Post-Concussion Symptoms, Quality of Life, and Mood after a Mild Traumatic Brain Injury

Moleac Pte Ltd: Moleac s NeuroAiDII Improves Post-Concussion Symptoms, Quality of Life, and Mood after a Mild Traumatic Brain Injury
finanznachrichten.de - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from finanznachrichten.de Daily Mail and Mail on Sunday newspapers.

David picardSylvain durrlemanStefan klotterValery feiginWorld congressName of press contactHead of medical affairs at moleacProfessor valery feiginRivermead post concussion symptoms questionnaireBrain injuryHospital anxietyDepression scaleMedical affairsPress contactLassen sie

Investegate |Moleac Pte Ltd Announcements | Moleac Pte Ltd: Moleac launches CognivAiD™, a novel targeted product for vascular dementia

Investegate announcements from Moleac Pte Ltd, Moleac launches CognivAiD™, a novel targeted product for vascular dementia

Sylvain durrlemanDavid picardHead of medical affairs at moleacName of press contactVascular dementiaMedical affairsCroci stigmaGinkgo foliumGinseng radixPress contactInvestegate announcementsInvestegate company announcementsMoleac pte ltdLobenewswire and globenewswire

Moleac launches CognivAiD™, a novel targeted product for vascular dementia

Moleac launches CognivAiD™, a novel targeted product for vascular dementia GlobeNewswire January 16, 2023 CognivAiD provides a long-awaited option to fulfil the unmet needs of patients with vascular dementia. CognivAiD demonstrated significant and clinically meaningful disease-modifying benefits in clinical trials based on VaDAS-Cog and ADCS-CGIC scales, with a favourable safety profile.CognivAiD has.

Sylvain durrlemanDavid picardHead of medical affairs at moleacName of press contactVascular dementiaMedical affairsCroci stigmaGinkgo foliumGinseng radixPress contact